ASCO GU 2022: Cytoreductive nephrectomy for patients with lung metastases
Cytoreductive nephrectomy is the surgical removal of the tumour to [...]
ASCO GU 2022: Cytoreductive nephrectomy for patients with tumour thrombus
Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number [...]
ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery
Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number [...]
Impact of cytoreductive nephrectomy in patients with metastatic kidney cancer
Cytoreductive nephrectomy is the removal of the tumour to reduce [...]
Selection of advanced kidney cancer patients for nephrectomhy
In this study, 6,043 patients with metastatic renal cell carcinoma [...]
Surgery after targeted therapy or immunotherapy for metastatic kidney cancer
A recent retrospective study (looking back at the patients’ cases [...]
Evidence in favour of active surveillance for small renal masses
Two studies presented at the American Urological Association 2020 Virtual [...]
ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer
Surgery to remove the kidney tumour is often the preferred [...]
Cytoreductive nephrectomy offers survival benefit in metastatic kidney cancer
The results of a trial looking at immunotherapy treatment with [...]
ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery
This interview with Dr Monty Pal, Associate Professor from the [...]
